US Patent

US11529352 — Preservation of immune response during chemotherapy regimens

Method of Use · Assigned to G1 Therapeutics Inc · Expires 2039-07-23 · 13y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of using a specific dosage regimen of a CDK 4/6 inhibitor in combination with chemotherapy and a checkpoint inhibitor to treat a tumor or cancer.

USPTO Abstract

The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3504 — trilaciclib-dihydrochloride

Patent Metadata

Patent number
US11529352
Jurisdiction
US
Classification
Method of Use
Expires
2039-07-23
Drug substance claim
No
Drug product claim
No
Assignee
G1 Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.